Pcn10 a Match-Adjusted Indirect Treatment Comparison (Maic) of Lenalidomide Plus Rituximab (R2) Versus Rituximab Plus Chemotherapy (R-Chemo) for Relapsed and/or Refractory (R/R) Follicular Lymphoma (Fl)

Abstract

were included (n=109). Demographic, clinical characteristics, treatment and outcomes for these patients were extracted from a hospital-based registry. Outcomes evaluated were the progression-free survival (PFS), OS and toxicities. Results: The baseline profile of patients was: mean (standard deviation) age of 65.9 (9.1) years; 86.1% of males; 54.1% of current smokers; and 82.3% with performance status 0-1. Half of patients were diagnosed with adenocarcinoma, 37.6% with squamous and the rest with other NSCLC types. Two third of patients (66.1%) were diagnosed with stage IV. 75.2% of patients received nivolumab as second line therapy and 21.1% as third line. 93.3% of patients had received platinum-based therapy as first line. The median PFS of nivolumab-treated patients was 3 (2, NR) months with a median treatment duration of 2.9 months. The median OS was not reached. 52 (47.4%) patients experienced one or more toxicity(s) during immunotherapy. The most frequent were pulmonary (13.9%) and gastrointestinal (13.9%) toxicities. No difference was detected in the PFS among patients with different histological type. Conclusions: This study provides useful insights regarding the real-world experience with nivolumab in Greece and the results are consistent with those of other real-world studies and clinical trials.

Matching-Adjusted Indirect Comparisons Applied for Comparative Efficacy of Haematologic Cancer Drugs within Health Economic Analysis

“…A Google search including all hits has returned 40 unique manuscripts and conference proceedings that were published between 2011 -February 2022 (excluding the three MAICs conducted and published for the purpose of this thesis), with half of them being published from 2020 onwards [71,73,. Of these, three were anchored MAICs [71,75,80], 16 were unanchored MAICs [78,79,84,85,90,91,[94][95][96][97]102,[107][108][109][110]112], and for 21 anchoring was not specified [73,76,77,[81][82][83][86][87][88][89]92,93,[98][99][100][101][103][104][105][106]111].…”

“…Most of the published MAICs were in relapsed/refractory [105][106][107][108][109][110][111][112] multiple myeloma [84][85][86][87][88][89][90][91], followed by chronic myeloid leukaemia [73,[80][81][82][83], relapsed/refractory diffuse large Bcell lymphoma [93][94][95][96][97][98], and relapsed/refractory follicular lymphoma [99][100][101][102]. The fewest MAICs were published in relapsed/refractory acute lymphoblastic leukaemia [71], and relapsed/refractory classical Hodgkin lymphoma [92], with one publication for each.…”

“…A clear differentiation between effect modifiers and prognostic factors was made in only three publications [97,102,106] of the 16 MAICs explicitly identified as "unanchored". Effect modifiers/prognostic factors have been listed without a justification of their source in 14 cases [73,75,80,82,84,87,88,91,93,94,100,103,106,111].…”

“…Effect modifiers/prognostic factors have been listed without a justification of their source in 14 cases [73,75,80,82,84,87,88,91,93,94,100,103,106,111]. Expert/clinician opinion was obtained in seven cases [78,95,97,101,102,104,105]. The relevant covariates were defined based on literature review [86,109] and on statistical significance [71,96], in two cases each.…”

“…Only two studies have reported on the weights distribution [77,78], while 16 studies have reported on the effective sample size [76][77][78]81,85,92,94,[95][96][97]101,[103][104][105]107,108]. Time-to-event endpoints have been assessed in 33 [71,73,[76][77][78][79][80][81][83][84][85][86][87][88][89][90][92][93][94][95][96][97][98]102,103,[105][106][107][108][109][110][111]…”